Press releases
- Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
- Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Key statistics
On Tuesday, Heron Therapeutics Inc (0J4V:LSE) closed at 3.20, -18.39% below its 52-week high of 3.92, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 3.20 |
Low | 3.20 |
Bid | -- |
Offer | -- |
Previous close | 3.20 |
Average volume | 3.17k |
---|---|
Shares outstanding | 150.65m |
Free float | 149.60m |
P/E (TTM) | -- |
Market cap | 482.09m USD |
EPS (TTM) | -0.6156 USD |
Data delayed at least 20 minutes, as of Jul 23 2024 18:51 BST.
More ▼